Orionin对急性肝衰竭小鼠的保护作用及其对肝组织细胞因子水平的影响*

doi:10.3969/j.issn.1672-5069.2017.03.010

实用肝脏病杂志 ›› 2017, Vol. 20 ›› Issue (3): 294-297.doi: 10.3969/j.issn.1672-5069.2017.03.010

Orionin对急性肝衰竭小鼠的保护作用及其对肝组织细胞因子水平的影响^*

邓怡林, 于合国, 施敏, 石翠翠, 范建高, 李光明

200092 上海市上海交通大学医学院附属新华医院消化内科（邓怡林,石翠翠,范建高,李光明）; 同仁医院消化内科（施敏）; 上海市计划生育科学研究所（于合国,刁华）

收稿日期:2016-10-14 出版日期:2017-06-10 发布日期:2018-03-10
通讯作者: 李光明,E-mail: ligm68@126.com
作者简介:邓怡林,女,25,硕士研究生。主要从事肝损伤及肝纤维化的防治研究。E-mail: yilindeng1991@163.com
基金资助:
*国家自然科学基金资助项目（编号：81400631/81570549）

Effect of oridonin on hepatic cytokine levels in mice with LPS/D-Gal-induced acute liver failure

Deng Yilin, Yu Heguo, Shi Min, et al.

Department of Gastroenterology,Xinhua Hospital Affiliated to Jiaotong University School of Medicine,Shanghai 200092,China

Received:2016-10-14 Online:2017-06-10 Published:2018-03-10

摘要/Abstract

摘要： 目的探讨冬凌草甲素（Oridonin）对脂多糖/D-氨基半乳糖氨（LPS/D-Gal）联合诱导的急性肝衰竭（ALF）小鼠的保护作用及其对肝组织细胞因子水平的影响。方法取150只小鼠,随机分成5组,每组 30 只。采用LPS/D-Gal腹腔注射建立小鼠ALF模型,设生理盐水对照组、Oridonin对照组、LPS/D-Gal诱导模型组和LPS/D-Gal处理及不同剂量Oridonin干预组。采用Real-time PCR法检测肝组织肿瘤坏死因子-α（TNF-α）、白细胞介素（IL）-1α、IL-1β和IL-6 mRNA水平。结果模型组小鼠48 h存活率为0.0% （0/30）,而两个Oridonin干预组小鼠48 h存活率分别提高至64.5% （19/30）和80.6% （24/30,P<0.01）; 组织病理学检查显示模型组小鼠肝细胞呈大块或/和亚大块坏死,肝小叶结构消失,残存肝细胞肿胀、空泡变性,肝窦肿胀充血,炎细胞浸润。Oridonin干预组小鼠肝细胞坏死、空泡变性和炎细胞浸润等较模型组有明显的改善;模型组小鼠血清ALT和AST水平分别为（345.3 ± 54.1） U/L和（500.2±53.5） U/L,明显高于对照组的[（42.3±0.6）U/L和（117.1±9.8）U/L,P<0.01],两个Oridonin干预组分别为（303.9±39.5） U/L和（340.6±2.8） U/L及[（130.2±38.3） U/L和（209.8±36.2） U/L,P<0.05];模型组小鼠肝组织TNF-α、IL-1α、IL-1β和IL-6 mRNA水平显著高于正常对照组（P<0.01）,而两个Oridonin干预组肝组织TNF-α、IL-1α、IL-1β和IL-6 mRNA水平显著低于模型组（P<0.01）。结论 Oridonin对LPS/D-Gal诱导的ALF小鼠具有显著的保护作用,其作用机制可能与降低肝组织细胞因子水平有关。

关键词: 急性肝衰竭, 脂多糖, D-氨基半乳糖氨, 冬凌草甲素, 细胞因子, 小鼠

Abstract: Objective To investigate the effect of oridonin on hepatic cytokine levels in mice with polysaccharide（LPS）/ D-galactosamine（D-Gal）-induced acute liver failure. Methods 150 mice were randomly divided into five groups（30 in each group）,e.g.,normal,oridonin control,model,oridonin-intervened,and oridonin-intervened for 12 days. ALF model was established in C57BL/6 mice by intraperitoneal injection of LPS/D-Gal. Results The 48 h lethality rate in LPS/D-Gal-induced group reached an extremely high level of 100%. However,the 48 h survival rates in two oridonin-intervened groups were 64.5% （19/30） and 80.6% （24/30,P<0.01）;The damage in liver tissues was ameliorated in mice pretreated with oridonin as compared with that in the model group;Serum ALT and AST levels in model group were（345.3±54.1） U/L and（500.2±53.5） u/L,significantly higher than those in control group[（42.3±0.6） U/L and（117.1±9.8） U/L,P<0.01] or in oridonin-treated group [（303.9±39.5） U/L and （340.6±2.8） U/L or [（130.2±38.3） U/L and （209.8±36.2） U/L,P<0.05];Administration of oridonin in mice with LPS/D-Gal-induced ALF significantly decreased mRNA levels of hepatic TNF-α,IL-1α, IL-1β and IL-6 compared with in model group（P<0.01）. Conclusion Oridonin has a protective effect on mice with LPS/D-Gal-induced ALF,and the mechanism might be related to inhibition of hepatic cytokine activities.

Key words: Acute liver failure, Lipopolysaccharide, D-galactosamine, Oridonin, Cytokines, Mice

邓怡林, 于合国, 施敏, 石翠翠, 范建高, 李光明. Orionin对急性肝衰竭小鼠的保护作用及其对肝组织细胞因子水平的影响^*[J]. 实用肝脏病杂志, 2017, 20(3): 294-297.

Deng Yilin, Yu Heguo, Shi Min, et al.. Effect of oridonin on hepatic cytokine levels in mice with LPS/D-Gal-induced acute liver failure[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 294-297.

参考文献

[1] Jedicke N,Struever N,Aggrawal N,et al.Alpha-1-antitrypsin inhibits acute liver failure in mice. Hepatology,2014,59(6):2299-2308.
[2] Guicciardi ME,Malhi H,Mott JL,et al.Apoptosis and necrosis in the liver. Compr Physiol,2013,3(2):977-1010.
[3] Brenner C,Galluzzi L,Kepp O,et al.Decoding cell death signals in liver inflammation. J Hepatol,2013,59(3):583-594.
[4] Gao SY,Li J,Qu XY,et al.Downregulation of cdk1 and cyclinb1 expression contributes to oridonin-induced cell cycle arrest at G2/M phase and growth inhibition in SGC-7901 gastric cancer cells. Asian Pacif J Cancer Prevent,2014,15(15):6437-6441.
[5] Wong AM,Zhang Y,Kesler K,et al.Genomic and in vivo evidence of synergy of a herbal extract compared to its most active ingredient:rabdosia rubescens vs. oridonin. Exp Ther Med,2010,1(6):1013-1017.
[6] Zhen T,Chen Z,Chen SJ.Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor like protein. Cancer Biol Ther,2012,4:127-138.
[7] Wang S,Yang H,Yu L,et al.Oridonin attenuates abeta1-42-induced neuroinflammation and inhibits NF-kB pathway. PLoS One,2014,9(8):e104745
[8] Lee W M,Squires R H,Jr.,Nyberg S L,et al. Acute liver failure:summary of a workshop. Hepatology,2008,47(4):1401-1415.
[9] Michael D. Josephs FRB,Fukuzuka K.Lipopolysaccharide and D-galactosamine-induced hepatic injury is mediated by TNF-α and not by Fas ligand. Am J Physiol Regulatory Integrative Comp Physiol,2000,278:1196-1201.
[10] Schwabe RF,Brenner DA.Mechanisms of Liver Injury. I. TNF-alpha-induced liver injury:role of IKK,JNK,and ROS pathways. Am J Physiol Gastrointest Liver Physiol,2006,290(4):G583-589.
[11] Luo M,Zhao A,Li J,et al.Acute liver injury attenuation of a novel recombinant sTNFR through blocking hepatic apoptosis. Immunopharmacol Immunotoxicol,2015,37(3):295-300.
[12] Silverstein R.D-galactosamine lethality model:scope and limitations. J Endotoxin Res,2004,10(3):147-162.
[13] Tunón M J.An overview of animal models for investigating the pathogenesis and therapeutic strategies in acute hepatic failure. World J Gastroenterol,2009,15(25):3086.
[14] Gill RQ,Ark S.Acute liver failure. J Clin Gastroenterol,2001,33(3):191-198.
[15] Li X,Gou C,Yang H,et al.Echinacoside ameliorates D-galactosamine plus lipopolysaccharide-induced acute liver injury in mice via inhibition of apoptosis and inflammation. Scand J Gastroenterol,2014,49(8):993-1000.
[16] Zhan Y,Wang Z,Yang P,et al.Adenosine 5'-monophosphate ameliorates D-galactosamine/lipopolysaccharide-induced liver injury through an adenosine receptor-independent mechanism in mice. Cell Death Dis,2014,5:e985.
[17] Pan CW,Zhou GY,Chen WL,et al.Protective effect of forsythiaside A on lipopolysaccharide/d-galactosamine-induced liver injury. Int Immunopharmacol,2015,26(1):80-85.
[18] Zhang J,Xu L,Zhang L,et al.Curcumin attenuates D-galactosamine/lipopolysaccharide-induced liver injury and mitochond-
rial dysfunction in mice. J Nutr,2014,144(8):1211-1218.
[19] Adams DH,Ju C,Ramaiah SK,et al.Mechanisms of immune-mediated liver injury. Toxicol Sci,2010,115(2):307-321.
[20] Xu Y,Xue Y,Wang Y,et al.Multiple-modulation effects of oridonin on the production of proinflammatory cytokines and neurotrophic factors in LPS-activated microglia. Int Immunopharmacol,2009,9(3):360-365.

Orionin对急性肝衰竭小鼠的保护作用及其对肝组织细胞因子水平的影响^*

Effect of oridonin on hepatic cytokine levels in mice with LPS/D-Gal-induced acute liver failure

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[2]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[3]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[4]	朱玉成, 闫家微, 孙景坤, 张秋月. 慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(5): 672-675.
[5]	张莹, 王洪岩, 迟程, 徐有青. LPS诱导的HepG2细胞NOTCH与LPS-TLR4-NF-κB炎症信号通路的“会话”研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 470-473.
[6]	张璇, 唐小云, 唐春银, 石学魁, 王惠琦, 张晓东, 沈海萍, 杨春辉. 中药方剂赤白汤对D-氨基半乳糖诱导的急性肝衰竭小鼠肠道菌群的影响研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 478-481.
[7]	裴颖, 黄峰, 殷宏振, 郭化磊. 去甲斑蝥酸钠对肝癌异位移植瘤小鼠肠道微生态的影响初探*[J]. 实用肝脏病杂志, 2019, 22(4): 486-489.
[8]	延喜胜, 李伟, 王剑. 酒精性肝病患者血清细胞因子水平和肠道菌群分布变化研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 518-521.
[9]	严玲玲, 胡东辉, 黄艳芳. 腺苷蛋氨酸联合多烯磷酯酰胆碱治疗妊娠期肝内胆汁淤积症患者临床疗效初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 530-533.
[10]	王媛, 党盼玉, 王伟. 血浆置换联合连续性血浆透析滤过治疗慢加急性肝衰竭患者临床疗效及其对血浆细胞因子水平的影响[J]. 实用肝脏病杂志, 2019, 22(4): 541-544.
[11]	彭思璐, 刘冰, 孙宏, 林剑, 潘志颖, 邓存良. HBV相关慢加急性肝衰竭患者预后及其影响因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 545-548.
[12]	郭乐乐, 张晓慧, 张向颖, 胡中杰, 任锋, 张晶. 对乙酰氨基酚诱导的急性肝损伤小鼠肝组织糖基转移酶Colgalt2表达的变化^*[J]. 实用肝脏病杂志, 2019, 22(1): 29-32.
[13]	陈海鸥, 刘适. 慢加急性乙型肝炎肝衰竭患者血清IL-10和GP73水平检测及其临床意义[J]. 实用肝脏病杂志, 2019, 22(1): 73-76.
[14]	马德渊, 马元凤, 张殿隆, 李山林. HBV相关慢加急性肝衰竭患者血清角蛋白18水平及其与患者预后的关系探讨^*[J]. 实用肝脏病杂志, 2019, 22(1): 77-80.
[15]	闫焕杰, 张淑芹, 赵文静. 自体骨髓干细胞移植治疗慢加急性乙型肝炎肝衰竭患者疗效初步研究[J]. 实用肝脏病杂志, 2019, 22(1): 81-84.